Australian Government
Department of Health
Therapeutic Goods Administration

Advisory Committee on Vaccines

Meeting Statement 30 – Friday 14 January 2022

Section A: Submissions for registration

The committee provided advice on two applications:

- major variation (change to dose regimen) for a vaccine with provisional registration for active immunisation to prevent COVID-19 (product name Comirnaty; active ingredient Tozinameran; sponsor Pfizer Australia Pty Ltd) that had been under evaluation from October 2021

- major variation (change to dose regimen) for a vaccine with provisional registration for active immunisation to prevent COVID-19 (product name Vaxzevria; active ingredient ChAdOx-1-S; sponsor AstraZeneca Pty Ltd) that had been under evaluation from November 2021.

Details of the ACV advice associated with these pre-market items has been released within the Australian Public Assessment Report (AusPAR). To browse all AusPARs see AusPAR search.

Section B: Safety

The committee was not asked to provide advice on a safety matter.

Further information

For further information on the ACV, please visit Advisory Committee on Vaccines

or contact the ACV by email ACV@health.gov.au.